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Abstract—From a network medicine perspective, diseases are
caused by perturbations in the dynamics of multiple interacting
genes - a disease module. A drug that is a suitable candidate
for re-purposing, should affect perturbed disease modules other
than the one for which it was designed. In other words, it
must act on various disease modules. A systematic analysis
of re purposing suitability requires deeper understanding of
drug target modularity. In this paper, we present a large-scale
analysis of drug-target relationships, evaluating the locality of
drug targets in protein-protein interaction networks. We show
that the various drugs in each category affect different regions in
biological networks, and present modular features. Additionally,
multiple targets associated to the same drug appear close in the
interactome. Our statistical analysis of the functions of the known
drug targets reveals that peripheral functions of disease modules,
such as signalling, are common targets for many drugs.
I. INTRODUCTION
Biological networks are used to describe the internal oper-
ation of an organism; they encompass different levels of ab-
straction and scope. Common biological networks are: protein-
protein interaction networks, gene transcription networks, gene
regulatory networks, signalling networks, metabolic networks,
and neural networks [1]. Each of this networks show a different
aspect of the processes and interactions of biological compo-
nents in an organism. In particular, molecular interactions of
a cell deﬁne an interactome.
The availability of high throughput methods, new sequenc-
ing techniques and computational annotation greatly increased
the number of high quality biological networks. High quality
networks collect manually curated interactions from experi-
mental data, and provide network methods the capability to
extract signiﬁcant results on analysis of complex biological
systems.
Given the level of complexity of the physiological systems
in play in human disease, the cause of a disease can rarely
be traced to a single gene but should rather be considered
a perturbation in the molecular interactions in the cell – the
disease module [7]. This network view of diseases [7] involves
a wider analysis that follows functional relationships, physical
interaction and metabolic pathways to decode the mechanisms
underlying complex diseases.
The modules of diseases with similar physiological char-
acteristics tend to be close in the interactome. The modular
nature of the diseases implies that diseases can be categorised
with respect to the physiological system they affect [5].
Categories such as Cancer or Neurological include diseases
that result from perturbations in close-by regions in the in-
teractome [5]. Furthermore, the modular nature of diseases is
also revealed through the analysis of disease phenotype [12],
[13].
Network analysis for drug repurposing resulted also in the
systemic analysis of drug and protein binding. Previous work
has shown that drug targets are rarely protein products of
essential genes, and a prevalence of intra modular protein
targets [14]. A further look onto phenotype can serve to
understand other aspects of drug target modularity.
Over 2,150 FDA (U.S. Food and Drug Administration)
approved drugs are listed in DrugBank [10], with about
1,700 targeting some of the 4,200 known protein targets. The
number of diseases greatly exceeds the indications available,
and with average costs for developing a new drug exceeding
£1,500 million, drug re-purposing of approved drugs is a
promising option. The need for comprehensive understanding
of the underlying mechanisms of diseases and drugs is still
an unresolved problem [8]; only the among heritable diseases
listed in the Online Mendelian Inheritance in Man (OMIM),
there are 7,800 different diseases such as Alzheimer’s and
Cancer.
In this paper we perform an exploratory analysis of the
genotypic and genotypic relation between drugs and heritable
diseases. Since drugs and diseases are a priori incomparable
sets, we propose a drug-disease category mapping, to deﬁne
an intended objective of drug design. We establish metrics
such as the locality and functional similarity of drug targets,
to quantify their speciﬁcity and possible side effects. The
locality of drug targets can be used to analyse the physical
mechanism of action drugs use to treat diseases. On the other
hand, functional similarity of drug targets reveals functions
that can be exploited for drug repursosing.
II. METHODS
First, we establish a mapping between diseases and drugs
to create a coarse model of drug target locality. The coarse
model will be useful to understand an underlying trend of
drug design. This approach allows us to create a novel
lax approximation to the drug target counterpart of disease
modules, i.e. drug target modules. Then, we describe the
AGRANDA, Simposio Argentino de GRANdes DAtos
46JAIIO - AGRANDA - ISSN: 2451-7569 - Página 48
measures we established to compare these modules, from their
structural genotype network properties, to the phenotype traits
they express.
A. Category mapping
Goh et. al. manually curated OMIM, and produced 21
disease categories to group diseases based on the physiological
system affected in 2005. The disease categories are: Bone,
Cancer, Cardiovascular, Connective tissue disorder, Derma-
tological, Developmental, Ear-Nose-Throat, Endocrine, Gas-
trointestinal, Hematological, Immunological, Metabolic, Mul-
tiple, Muscular, Neurological, Nutritional, Ophthalmologic,
Psychiatric, Renal, Respiratory and Skeletal. We bring up to
date the mapping by including recent OMIM disease to gene
associations (downloaded on March 30, 2017) for each of the
curated diseases.
DrugBank groups drugs into Anatomical Therapeutic
Chemical (ATC) categories, according to the physiological
system affected by a drug and therapeutic properties [10].
The ATC classiﬁcation is hierarchical, where the top level
categories represent the most general elements. We considered
that drugs belonging to a speciﬁc category in DrugBank have
an effect on all the diseases in the corresponding physiological
category presented by Goh et.al. Naturally, not all ATC
categories will match a Goh category, such as the top level
category J - Antiparasitic products, insecticides and repellents,
as those drugs are not designed to target humans, but foreign
organisms.
The analysis was performed in the 2017 released 5.05
DrugBank XML ﬁle. A summary of drugs per ATC category
is included in Table I. Notice that each drug can belong to
multiple ATC categories, so the total number of drugs is not
the sum of the individual categories.
Category Total FDA approved
A 268 233
B 107 96
C 245 221
D 156 140
G 126 117
H 50 45
J 235 220
L 235 216
M 106 91
N 345 302
P 46 39
R 166 145
S 147 141
V 111 102
N/A 6298 414
Overall 8257 2157
TABLE I: Drugs found in DrugBank per top level ATC
category.
We notice that not all Goh categories map naturally to ATC
categories, thus DrugBank’s pharmacological action categories
are used as fallback whenever the Goh category did not match
an ATC category. The Multiple Goh category has been left
unmatched, as each disease requires an independent drug asso-
ciation. Furthermore, the Muscular and Skeletal were merged
into a Musculoskeletal category, as we found no good way
to separate the musculoskeletal drugs into each independent
category. A summary of the FDA approved drugs, drug targets
and disease proteins per category is shown in Table II.
Categories Elements
Goh ATC DBCat Diseases Drugs
Bone - 89, 2165 52 25
Cancer L01 - 198 138
Cardiovascular C, V09G - 98 223
Connective tissue V03AK - 49 0
Dermatological D - 95 140
Developmental H01 - 51 21
Ear-Nose-Throat S02 2159, 2106 52 62
Endocrine L02 - 99 22
Gastrointestinal A03 - 34 25
Hematological B - 157 96
Immunological L[03,04] - 105 58
Metabolic A[09,14,15,16] - 291 32
Musculoskeletal M - 167 91
Neurological N - 270 302
Nutritional - 234, 2733 12 47
Ophthalmologic S01 - 149 137
Psychiatric - 529 26 47
Renal - 629 59 14
Respiratory R - 22 145
Overall 1928 1302
TABLE II: Category mapping. The Categories column shows
how diseases from Goh categories map drugs from ATC or
DrugBank categories; - indicates no mapping between the
Disease category and the Drug category. The Elements column
shows the number of drugs and diseases per category.
Over 60% of FDA approved drugs were mapped to a Goh
category. We believe that this is a good coverage of the
drug set, and by broadening the mapping we may reduce the
conﬁdence in the associations of drugs to Goh categories.
B. Physical distance of proteins
The interactome can provide systemic information about a
set of proteins. Neighbour proteins in the interactome are inter-
actors, and clusters of proteins are likely to share function [13].
We consider that the distance between drug targets can offer
perspective into mechanism of action for drug repurposing.
Generally speaking, close targets will share the effect, while
distant targets will have different effects.
In our analysis, the distance between two proteins is the
minimum path length between a pair of proteins in an un-
weighted and undirected graph, that represents the protein-
protein interaction (PPI) network given by the Human Protein
Reference Database (HPRD) [15]. The HPRD PPI is hand
curated, and provides high quality, experimentally veriﬁed
protein-protein interactions.
Since many of the comparisons needed are among sets of
targets, a fair measure must be established for sets of distances.
We use an unequal variances t-test (or Welch’s t-test), to
compare if the distances from a pair of sets comes from the
same distribution. It is formally deﬁned as:
t =
A¯− B¯q
σ2A
|A| +
σ2B
|B|
,
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where A,B are sets of values, and X¯ is the mean, σ2X
is the variance and |X| is the size of set X . The t-statistic
can be later translated to a conﬁdence p-value according to
the degrees of freedom associated to the variance estimates.
Typical conﬁdence values to conﬁrm that the sets come from
different distributions are p-value < 0.05 or p-value < 0.01.
C. Functional relation of proteins
We characterise the phenotype of a gene by the aggregation
of functions performed by the proteins it produces. We obtain
gene functions from the Gene Ontology (GO), and calculate
the most signiﬁcant functions per category. Moreover, the
functional relation of drug targets can be analysed by com-
paring mathematical models of the function distribution per
category.
The Gene Ontology is a taxonomy designed with the aim
to standardise the description of genes and gene products
across databases, that is, it describes a unique vocabulary
for all organisms. The taxonomy is divided in three major
domains, namely: biological process, cellular component and
molecular function. As with most taxonomies, it is presented
as an up-rooted structure, in which the terms are arranged in
ever increasing speciﬁcity, with the root being the less speciﬁc
term and leaves the most speciﬁc terms [6]. This ontology
is used to annotate proteins. That is, we can assign a set of
terms to a protein that will describe it without ambiguity while
allowing for a clear understanding of the current information
available.
Running statistical tests on the annotated gene ontology
terms is a common approach to ﬁnd the most relevant functions
performed by sets of proteins. The terms that appear signiﬁ-
cantly more annotated by the proteins in the set of interest, in
contrast to the terms annotated by all human proteins, deﬁne
the relevant functional categories of the set of proteins. This
approach is known as a Gene Ontology over-representation
analysis. Some of the common statistical models are the χ2,
and Fisher’s exact test [2]. We use the Fisher’s exact test as we
want conservative estimates in the number of over-represented
GO categories.
Furthermore, semantic similarity calculations in the Gene
Ontology produce a quantiﬁable measure of relatedness of
genes and gene products. That is, the produce is a single
number that quantiﬁes the functional similarity of two terms
in the ontology, and since proteins are annotated by terms
in the ontology, their function can be compared by way
of the semantic similarity of the annotating terms [4]. We
calculate the semantic similarity for every GO term in the
Molecular Function and Biological Process domains, as they
reveal functional aspects of the drug targets. The Resnik sim-
ilarity is calculated with GOssTo [16] on the GO annotations
downloaded on April 5, 2017.
To ﬁnd the signiﬁcance of the functional similarity within
a set, we characterise pairwise semantic similarities between
all terms. The difference between the domain and the category
distribution of terms hints how speciﬁc is the mechanism of
action of the drug category.
Term sets are characterised by a random variable distribu-
tion. However, to the best of our knowledge there is no known
term distribution for these sets. Therefore, we tested every
random variable distribution from the Python SciPY library to
ﬁt the model. We want a random variable which approximates
both the cumulative distribution and the mean of similarities.
The real cumulative distribution for a collection of simi-
larity values x is given by the cumulative histogram Hi(x).
Formally, the cumulative distribution of the ﬁrst i similarity
bins is:
Hi(x) =
iX
j=1
hj(x)
where hj(x) (bin j for the histogram of x) is the amount
of elements in x between the boundaries bj−1 and bj . The
similarity boundaries b = (b0, . . . , bn) ∈ Rn are equally
distributed between the minimum and maximum similarity
values, with b0 = min{x} and bn = max{x}.
Therefore, we pick the random variable distribution which
minimises J for both domains:
J = (0.5− F (x¯))2 + 1
n
nX
i=1
(Hi(x)− F (bi))2 ,
where x¯ is the mean of x, and F (bi) is the ﬁtted cumulative
distribution function of the random variable at the similarity
value bi.
The half logistic distribution is the consensus best ﬁt in the
domains. The cumulative distribution function is:
F (k) =
1− e−k
1 + e−k
We consider the similarity of a category signiﬁcant if the
mean of the category is above 80% of the domain cumulative
distribution. This is, the mean similarity of the category is
among the top 20% percentile of similarity values in the sub
ontology.
III. ANALYSIS
The ﬁrst analysis is intended to get a basic genotype
relation between drugs. The second experiment is intended
to select the most important molecular functions performed
by drug targets. Finally, the third experiment characterises
the phenotype relation between the most important molecular
functions from the drug targets.
A. Drug targets and known disease proteins
To clarify the nature of the drug-disease relationship, we
extracted the disease proteins from all known heritable dis-
eases in OMIM and counted the number of drug targets that
are known diseases associated proteins. Table III shows the
number of shared proteins between diseases and drugs per
category.
We observe that only 137 proteins from the 306 common
proteins (e.g. disease proteins that are also drug targets) are in
the same class. This means that more than half of the common
proteins targeted by drugs, are speciﬁc to diseases from other
categories.
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Category Disease Proteins Drug Targets Overlap
Bone 42 51 4
Cancer 195 298 26
Cardiovascular 129 318 18
Connective tissue 98 0 0
Dermatological 147 316 2
Developmental 51 38 2
Ear-Nose-Throat 40 200 0
Endocrine 98 46 5
Gastrointestinal 34 29 0
Hematological 101 233 22
Immunological 163 140 10
Metabolic 247 104 13
Musculoskeletal 115 179 3
Neurological 251 367 22
Nutritional 19 195 1
Ophthalmologic 97 308 6
Psychiatric 31 81 7
Renal 48 56 1
Respiratory 45 232 6
Overall 1554 1280 306
TABLE III: Break-down of proteins per category. The Dis-
ease proteins column shows the number of different proteins
that belong to a disease from each category. Correspondingly,
the Drug Targets category shows the number of different
proteins targeted by a drug from each category.
Fig. 1: Heatmap of the Jaccard coefﬁcient between disease
proteins and drug targets by category. Colors are based on the
Jaccard coefﬁcient, while labels indicate the actual number of
common elements in the categories.
We calculate the Jaccard coefﬁcient between all disease and
drug categories the to further explore how common proteins
are distributed. The Jaccard coefﬁcient measures the diversity
of the elements of two sets. Formally:
J(A,B) =
|A ∩B|
|A ∪B| ,
where A and B are sets of elements. Figure 1 shows the
resulting comparison (notice that the diagonal of the matrix
is equal to the Overlap column from Table III).
We can clearly see that drugs do not exclusively target
diseases from the same category. While some disease cat-
Fig. 2: Heatmap of target distance for category pairs. Colors
indicate the average distance between all drug targets from
category A to targets from category B.
egories are preferentially targeted by drugs from the same
category, most do not show this behaviour. In particular, Bone,
Cancer, Cardiovascular, Developmental, Hematological, Im-
munological, Neurological, and Psychiatric diseases proteins
are preferentially targeted by drugs from the same category.
On the other hand, Endocrine, Nutritional, and Renal diseases,
are preferentially targeted by Cardiovascular, Psychiatric and
Cardiovascular drugs respectively. Metabolic diseases are tar-
geted more preferentially by Cardiovascular, Hematological
and Nutritional drugs than by Metabolic drugs.
B. Physical distance between drug proteins
According to the network view of diseases, a disease is
a wider perturbation in the interactome. To verify whether a
drug was targeting the wider disease module, we analysed the
distance of the target proteins for the mapped drug categories.
Figure 2 shows that intra-category proteins are not in general
closer than inter-category proteins, with the exception of
Cancer and Endocrine drugs. This seems to indicate that most
drugs do not affect speciﬁc modules in the network, but rather
target proteins which have an indirect effect on the disease.
Although disease genes cluster in the interactome [7], the
entire set of disease genes is not much closer than random
proteins from the interactome. The average distance between
all disease genes is 3.45, while the average interactome dis-
tance is 3.58. Drug targets appear to be somewhat closer than
random genes, with an average distance of 3.25. Welch’s t-
test conﬁrms that the distance distribution from drug targets is
signiﬁcantly different from a random choice in the interactome
(p-value < 1.0× 10−300). The slight modularity suggests that
there are some functions which are particularly good as gene
targets.
We focus on particular categories that are representative
among all drugs to describe the intra-category relation of
drug targets. Cancer and Endocrine drugs are selected because
they have closer intra-category targets. On the other hand,
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Nutritional drugs are selected because they have the furthest
intra-category targets. Finally, Neurological drugs are selected
as the largest drug category.
(a) Cancer (b) Endocrine
(c) Neurological (d) Nutritional
Fig. 3: Heatmaps target distance for drug pairs within a
category. Colors indicate the average distance between targets
from drug A to targets from drug B.
Figure 3 shows the details of the intra category distances
of the drugs. Note that the main diagonal of each heatmap is
signiﬁcantly closer than the average. This is expected as in
the main diagonal, the targets of a single drug are compared
between each other. This distance will be zero only in the case
that the drugs have a single target. Notice that these ﬁgures are
not “zoom-in”s into diagonal elements from Figure 2; while in
Figure 2 each target is included only once, in Figure 3 drugs
can that share targets become closer. Table IV shows how the
intra-category distances look from both perspectives.
Cancer drugs not only share the largest amount of targets
with other categories (Figure 1), but also have closer targets
with drugs from other categories (Figure 2).
The largest group of drugs from a single category that target
the same protein belongs to the Endocrine category. Four drugs
target Gonadotropin-releasing hormone receptor (GNRHR):
Degarelix, Histrelin, Leuprolide, and Triptorelin. Endocrine
drugs act in the tightest module among drug categories.
Drug targets from Neurological drugs appear to be randomly
distributed in the interactome. Even if some drugs target
speciﬁc disease genes, most targets do not lie in a module.
Nutritional drugs target genes that are more distant than
the average of the interactome. Manual curation of the drugs
reveals a clearly signiﬁcant group of drugs within this category.
Many Nutritional drugs are dietary supplements, which on
their own are different enough to not target any speciﬁc
module.
Category by Category by Drug
Bone 3.13 2.54
Cancer 3.06 2.95
Cardiovascular 3.39 3.27
Dermatological 3.42 2.86
Developmental 3.35 3.06
Ear-Nose-Throat 3.34 3.06
Endocrine 3.05 2.50
Gastrointestinal 3.19 2.52
Hematological 3.40 3.12
Immunological 3.30 2.99
Metabolic 3.52 3.42
Musculoskeletal 3.32 3.44
Neurological 3.50 3.33
Nutritional 3.66 3.40
Ophthamological 3.41 3.30
Psychiatric 3.48 3.12
Renal 3.46 3.02
Respiratory 3.33 2.96
Total 3.38 3.26
TABLE IV: Average distance per category. The columns
show how target genes are grouped. Every target from any
drug is included once when grouped by Category, while every
target is included as many times as it appears like a drug target
when grouped by Drug.
Fig. 4: Histogram of target distance for drugs with multiple
targets. Lower distance values are better. N.C. means that the
target proteins are not connected in the interactome.
Another interesting analysis is checking the distance of the
protein targets for drugs that have multiple targets. If the
targets of a drug are close in the interactome, the drug affects a
module. Otherwise, the drug is affecting multiple modules and
hints to other possible effects of that drug — e.g. side-effects.
Figure 4 shows that the proteins from multi target drugs are
closer than average proteins in the human interactome.
C. Functional relation of target proteins
Since drugs appear to affect non cohesive portions of the
network, it is important to analyse the target proteins with
respect to their function.
We have performed a Gene Ontology over-representation
analysis using the Fisher’s exact model with a Bonferroni
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correction [3] to obtain the signiﬁcant functional categories
that represent the drug target proteins. Table V shows the
10 most over-represented GO terms for the proteins in each
category, and their information content. It can readily be seen
that most categories represent signalling, transport or binding
processes, indicating that drug compounds target peripheral
signalling mechanisms to produce their effect.
Category GO Term Name Inf. Cont.
C
an
ce
r
GO:0044323 retinoic acid-respon 8.71
GO:0015858 nucleoside transport 8.71
GO:0006145 purine nucleobase ca 8.71
GO:0004666 prostaglandin-endope 8.71
GO:0003918 DNA topoisomerase ty 8.71
GO:0004517 nitric-oxide synthas 8.30
GO:0034875 caffeine oxidase act 8.01
GO:0009820 alkaloid metabolic p 8.01
GO:0005452 inorganic anion exch 8.01
GO:0048384 retinoic acid recept 7.79
E
nd
oc
ri
ne
GO:0004769 steroid delta-isomer 8.71
GO:0050294 steroid sulfotransfe 8.01
GO:0034875 caffeine oxidase act 8.01
GO:0034056 estrogen response el 8.01
GO:0009820 alkaloid metabolic p 8.01
GO:0030284 estrogen receptor ac 7.79
GO:0009404 toxin metabolic proc 7.79
GO:0002933 lipid hydroxylation 7.79
GO:0016098 monoterpenoid metabo 7.61
GO:0006068 ethanol catabolic pr 7.45
N
eu
ro
lo
gi
ca
l
GO:0086043 bundle of His cell a 8.71
GO:0071886 1-(4-iodo-2,5-dimeth 8.71
GO:0052834 inositol monophospha 8.71
GO:0048630 skeletal muscle tiss 8.71
GO:0045777 positive regulation 8.71
GO:0019371 cyclooxygenase pathw 8.71
GO:0014827 intestine smooth mus 8.71
GO:0009804 coumarin metabolic p 8.71
GO:0008292 acetylcholine biosyn 8.71
GO:0005219 ryanodine-sensitive 8.71
N
ut
ri
tio
na
l
GO:0070814 hydrogen sulﬁde bio 8.71
GO:0047057 vitamin-K-epoxide re 8.71
GO:0042167 heme catabolic proce 8.71
GO:0035408 histone H3-T6 phosph 8.71
GO:0035403 histone kinase activ 8.71
GO:0017187 peptidyl-glutamic ac 8.71
GO:0009804 coumarin metabolic p 8.71
GO:0004666 prostaglandin-endope 8.71
GO:0004485 methylcrotonoyl-CoA 8.71
GO:0004357 glutamate-cysteine l 8.71
TABLE V: Over-represented terms per category. The GO
Term and Name columns identify the over-represented GO
term, and Inf. Cont. indicates the information content of the
term (the higher the better).
To verify that the over-represented proteins form a function-
ally coherent group, we have calculated the semantic similarity
of the over-represented terms. We show that the function
of the proteins in the over-represented group is signiﬁcantly
different than the overall function of the proteins in the human
genome. Figure 5 compares how the signiﬁcant terms from the
molecular function and biological process domains separate
from all annotations in the Gene Ontology. The signiﬁcant
terms from the drugs appear closer than expected by random
chance; therefore, drugs target proteins from genes which are
functionally related. Furthermore, ﬁgures 6 and 7 show the
(a) Molecular Function (b) Biological Process
Fig. 5: Histogram of semantic similarity in the domains.
Higher values of similarity indicates that the function is closer.
distribution of semantic similarity scores for the preselected
drug categories.
(a) Cancer (b) Endocrine
(c) Neurological (d) Nutritional
Fig. 6: Histogram of semantic similarity for speciﬁc groups
in the molecular function domain. Higher values of similarity
indicates that the function is closer.
The p-value column from Tables VI and VII show the
conﬁdence percentile by which we can reject that the sample,
and the set of all the similarity values, come from the same
distribution. The samples are the similarity values between
every pair of over represented GO term in each category. This
was done performing a one tailed t-test (since each distribution
has a lower mean than the set of all the similarity values), on
the samples and the set of all the similarity values for the
biological process and the molecular function domains.
A review of Tables VI and VII reveals that all over repre-
sented categories have some preferential functions compared
to the entire domain. This supports the evidence found by
the physical distance between drug targets. Furthermore, some
categories such as Bone and Renal are extremely speciﬁc in
target functions.
The function of Cancer drugs is not very speciﬁc, in fact it
shows as the least speciﬁc category in the biological process
domain (Table VII). This fact is supported by the closeness
of Cancer drug targets to other category targets presented in
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(a) Cancer (b) Endocrine
(c) Neurological (d) Nutritional
Fig. 7: Histogram of semantic similarity for speciﬁc groups
in the biological process domain. Higher values of similarity
indicates that the function is closer.
Category Mean Percentile p-value
Bone 1.92 4.3 1.71× 10−02
Cancer 0.91 28.1 2.87× 10−03
Cardiovascular 0.77 35.3 7.48× 10−05
Dermatological 1.28 14.6 4.76× 10−18
Developmental 1.64 7.4 4.65× 10−02
Ear-Nose-Throat 0.92 27.8 4.93× 10−04
Endocrine 1.16 18.0 1.13× 10−02
Gastrointestinal 1.79 5.5 1.23× 10−02
Hematological 0.85 31.1 3.72× 10−05
Immunological 0.98 25.1 5.09× 10−03
Metabolic 1.17 17.7 3.82× 10−03
Musculoskeletal 0.88 29.7 8.10× 10−05
Neurological 0.88 29.6 2.92× 10−08
Nutritional 1.13 18.9 2.31× 10−05
Ophthamological 0.88 29.8 1.08× 10−05
Psychiatric 1.17 17.9 2.90× 10−04
Renal 1.63 7.5 4.01× 10−04
Respiratory 0.85 31.2 2.78× 10−04
TABLE VI: Semantic similarity signiﬁcance in the molec-
ular function domain. We consider categories with means
within the top 20 percentile to be signiﬁcantly closer than the
domain average.
the previous section. Cancer drugs are known to have large
amounts of side effects and are used as an extreme measure
[17].
IV. CONCLUSION
The construction of a categorical drug to disease mapping
allows the usage of an evolving platform for drug and dis-
ease comparison. As DrugBank annotates drugs, they can be
included into the deﬁned categories. Although our analysis is
centred on FDA approved drugs, the category mapping is not
bounded to that restriction. These features allow the mapping
to be useful also in experimental drug analysis.
Category Mean Percentile p-value
Bone 1.46 7.8 3.40× 10−10
Cancer 0.66 38.0 6.24× 10−03
Cardiovascular 0.67 37.5 2.67× 10−06
Dermatological 0.79 30.1 5.63× 10−10
Developmental 1.30 10.8 1.16× 10−03
Ear-Nose-Throat 0.90 24.4 4.08× 10−12
Endocrine 1.57 6.1 3.23× 10−14
Gastrointestinal 1.33 10.3 6.61× 10−06
Hematological 1.01 19.5 3.35× 10−26
Immunological 0.85 26.6 1.23× 10−11
Metabolic 1.68 4.8 1.59× 10−07
Musculoskeletal 0.78 30.7 1.59× 10−05
Neurological 0.72 34.0 2.46× 10−08
Nutritional 1.29 11.1 1.44× 10−23
Ophthamological 0.84 27.1 4.61× 10−11
Psychiatric 0.98 21.0 2.98× 10−07
Renal 1.60 5.8 8.50× 10−06
Respiratory 0.86 26.3 4.25× 10−10
TABLE VII: Semantic similarity signiﬁcance in the bio-
logical process domain. We consider categories with means
within the top 20 percentile to be signiﬁcantly closer than the
domain average.
While the principles behind disease modules have been
studied in recent years, little is known about how drugs interact
with them. The formalisation of concepts and procedures to
approach their drug target counterparts provides a computa-
tional basis to analyse this relation. Moreover, the study of
drug targets can help in the understanding and characterisation
of disease modules and functional gene modules.
The initial analysis of drug categories shows that while
drugs targets from speciﬁc categories are modular, the mech-
anisms used to produce an effect do not strictly co-localise
with the disease modules. Additionally, we ﬁnd that the
preferred target are proteins used for signalling, transport or
binding processes. This suggests that the comprehension of
disease modules might beneﬁt from the usage of different
biological networks, such as signalling networks. Drugs that
have common functions are interesting for repurposing effects.
The analysis of multi target drugs could also be useful
for drug repurposing, as their multiple targets can relate to
different diseases. Multi target drugs are also interesting when
the targets are close, since they target the same module. This
further adds to the potential of drugs to enhance the disease
modules.
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